Glycomacropeptide for Management of Insulin Resistance and Liver Metabolic Perturbations

Background and Aims: The increasing prevalence and absence of effective global treatment for metabolic syndrome (MetS) are alarming given the potential progression to severe non-communicable disorders such as type 2 diabetes and nonalcoholic fatty liver disease. The purpose of this study was to inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauvé, Mathilde Foisy, Feldman, Francis, Koudoufio, Mireille, Ould-Chikh, Nour-El-Houda, Ahmarani, Lena, Sane, Alain, N’Timbane, Thierry, El-Jalbout, Ramy, Patey, Nathalie, Spahis, Schohraya, Stintzi, Alain, Delvin, Edgard, Levy, Emile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469639/
https://www.ncbi.nlm.nih.gov/pubmed/34572325
http://dx.doi.org/10.3390/biomedicines9091140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469639/
https://www.ncbi.nlm.nih.gov/pubmed/34572325
http://dx.doi.org/10.3390/biomedicines9091140

Ejemplares similares